There is substantial evidence that genetic events are associated with the etiology of brain tumors. The purpose of this study is to characterize the cancer risk in a large number of kindreds of glioma patients using combined epidemiologic and statistical techniques and incorporating molecular genetic markers. We will continue to accrue families to obtain a sufficiently large sample size to have precise estimates of the heritable component of gliomas. Several types of analyses will be performed on the data set. First, a descriptive analysis to detect overall cancer excess or excess of specific sites by computing Standardized Incidence Ratios (SIRs). The SIRs will determine whether excess cancer exists in first-degree relatives of glioma patients, by specific site, or by specific proband or relative characteristics. The next type of analysis is hypothesis testing using segregation analysis (with the computer program, Statistical Analysis for Genetic Epidemiology - SAGE) to determine the genetic model and parameter estimates that characterize the mode of inheritance of gliomas and identify specific kindreds showing evidence for a major gene to include in linkage analysis. Through linkage candidate gene analysis we will determine if mutations at distinct cancer predisposing loci are etiologically relevant and inherited from an antecedent relative. The candidate gene analysis will be conducted by Dr. Peter O'Connell at The University of Texas Health Science Center at San Antonio. With a larger sample we will be able to confirm our finding that patients with multifocal glioma, gliomas as a second malignancy, and a family history constitute a genetically predisposed subgroup. This study will be the first comprehensive evaluation of familial aggregation in families of unselected glioma patients. In addition, we are collecting blood from each new patient and our specimen repository will be available to study future candidate genes to integrate with the family data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055261-07
Application #
6102725
Study Section
Project Start
1999-02-01
Project End
2000-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Liu, Yanhong; Shete, Sanjay; Hosking, Fay et al. (2010) Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev 20:239-44
Puduvalli, V K; Sampath, D; Bruner, J M et al. (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-43
Levin, Victor A; Hess, Kenneth R; Choucair, Ali et al. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981-90
Puduvalli, Vinay K; Hashmi, Masood; McAllister, Leslie D et al. (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259-66
Wrensch, Margaret; Minn, Yuriko; Chew, Terri et al. (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-99
Berrak, Su Gulsun; Ozek, Memet M; Canpolat, Cengiz et al. (2002) Association between DNA content and tumor suppressor gene expression and aggressiveness of atypical teratoid/rhabdoid tumors. Childs Nerv Syst 18:485-91
de Andrade, M; Barnholtz, J S; Amos, C I et al. (2001) Segregation analysis of cancer in families of glioma patients. Genet Epidemiol 20:258-70
Davies, M A; Koul, D; Dhesi, H et al. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59:2551-6
Sano, T; Lin, H; Chen, X et al. (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820-4
Levin, V A (1999) Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro Oncol 1:69-80

Showing the most recent 10 out of 36 publications